Check out the latest article from Hannah Clarke in Urology Times on data in mCRPC from our collaboration with Dr. Jacob Berchuck of Winship Cancer Institute of Emory University at #ISLB24 and #AACRLBx24. View article: https://lnkd.in/gd5RfkSz #ProstateCancer #PSMA #DrugDevelopment #LiquidBiopsy #Epigenomics
Precede Biosciences
生物技术研究
We're impacting precision medicine with a first-in-class ?? liquid biopsy platform
关于我们
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology.? Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.? By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.
- 网站
-
https://www.precede.bio/
Precede Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Boston, MA
- 类型
- 私人持股
- 创立
- 2021
- 领域
- biotechnology、oncology、plasma、precision medicine、genomic liquid biopsy、drug development、biology、human biology、human biology、cancer、molecular biology、machine learning、ai、artificial intelligence、genomic medicine和target medicines
地点
-
主要
获取路线
US，Boston, MA
Precede Biosciences员工
动态
-
#SABCS24 abstracts are out! Join Jonathan Beagan and our team from Precede Biosciences for a poster spotlight session highlighting the latest data for our #LiquidBiopsy platform in stratifying patients with ER+ breast cancer for therapy selection. View abstracts: https://bit.ly/3AY96c6 #BreastCancer #PrecisionMedicine #DrugDevelopment #SERDs
-
-
Precede Biosciences Unveils AACR LBx 2024 Data on Blood Test for Tumor PSMA and Lutetium-PSMA Response in mCRPC Rehan Verjee Jacob Berchuck https://lnkd.in/eB2VQh37 #AACR?#AACRLBx2024?#Cancer?#LutetiumPSMA?#mCRPC?#OncoDaily?#Oncology?#PrecedeBiosciences?#ProstateCancer?#PSATesting?#PSMA #PETScan?#Medicine #Health
-
-
Today Precede Biosciences released data presentations from #aacrLBx24, including new data with our collaborator Dr. Jacob Berchuck demonstrating the ability to stratify #mCRPC patient response to Lutetium-PSMA by inferring tumor #PSMA expression from a simple blood test. View press release: https://bit.ly/3ALitvO #LiquidBiopsy #ProstateCancer #ComprehensiveEpigenomics #PrecisionMedicine #DrugDevelopment
-
-
Precede Biosciences is excited to announce the latest data presentation with our collaborator, Dr. Jacob Berchuck from Winship Cancer Institute of Emory University, to be presented at #aacrLBx24 on November 15. These data demonstrate stratification of response to Lutetium-PSMA-directed therapy based on tumor PSMA expression as determined by our comprehensive epigenomic liquid biopsy platform.?View abstract: https://bit.ly/3Aw0qJZ
Abstract B002: Determination of tumor PSMA expression and response to Lutetium-PSMA in men with prostate cancer using a novel epigenomic liquid biopsy platform
aacrjournals.org
-
Co-founder & President, PMWC Intl / 33,000 LI Followers / PMWC Newsletters 92,000+ subscribers since 2009- SORRY, UNABLE TO ACCEPT MORE CONNECTIONS DUE TO THE LINKEDIN LIMIT
Cancer Fragmentation, Multi-Cancer Detection & Liquid Biopsy Innovation at PMWC 2025 (Feb. 5-7), Santa Clara Convention Center in California. Liquid biopsy is reshaping oncology, enabling non-invasive insights into tumor biology, monitoring treatment response, and catching early signs of relapse. This approach is transforming staging, identifying therapeutic targets, and understanding resistance mechanisms, with clinical studies affirming its impact. Highlights on Feb 6th in Track 4 - Liquid Biopsy: ?? Keynotes: Early Cancer Detection with DELFI Technology - Victor Velculescu (Johns Hopkins) Circadian Rhythms & CTC Metastasis - Dr. Nicola Aceto (ETH Zurich) ?? Panels: --Innovative Approaches in Liquid Biopsy - Chaired by Victor Velculescu, featuring Adam Widman (MSKCC) --CTCs: The New Frontier - Chaired by Nicola Aceto, with Min Yu, (University of Maryland) & Matteo Ligorio (UTSW) --Improving Sensitivity of MRD and MCED - Chaired by Adrian Lee, with Jonathan Beer (BMS), C. Ola Landgren, M.D., Ph.D. (UMiami), & Marija Balic (UPMC) --Sequencing for Early Detection - Featuring Alex Sockell, PhD (PacBio), James Hadfield (AstraZeneca), & Cristian Tomasetti (City of Hope) --Innovations Across Cancer Continuum - Led by Tomasz (Tom) Beer (Exact Sciences), with Elizabeth O'Donnell, MD, DipABLM (Dana-Farber) & Arnaud PAPIN (Merck) --Multi-Cancer Early Detection - Chaired by Peter B. (DELFI Diagnostics), with Joshua Cohen (Haystack MRD? by Quest Diagnostics?), Lauren C. Leiman (BLOODPAC), & Joshua Ofman MD, MSHS (GRAIL) --Showcase: Wendy Winckler (Droplet Biosciences, Inc), Varsha Rao (Claret Bioscience), Matthew Pink (Biodesix, Inc.), J.Carl Barrett (Precede Biosciences) ?? Join PMWC 2025 in Silicon Valley (Feb 5-7) to connect with oncology pioneers tackling the future of cancer care. ?? Register now to secure your place! https://lnkd.in/g9j9UnKS #PMWC25 #PrecisionMedicine #LiquidBiopsy #Oncology #CancerResearch #HealthcareInnovation PMWC - Precision Medicine World Conference, DeciBio, International Society of Liquid Biopsy #AACR24
-
-
Precede Biosciences’ latest abstract highlighting our novel comprehensive epigenomic liquid biopsy platform’s potential to inform drug development, cancer biology, and therapy selection has been selected as a “proffered talk from highly-rated abstracts” to be presented by J.Carl Barrett at #aacrLBx24. View abstract: https://bit.ly/3YQtVyb #ComprehensiveEpigenomics #LiquidBiopsy #PrecisionMedicine #DrugDevelopment
-
-
Thank you DeciBio for hosting the Emerging Applications and Platforms in Liquid Biopsy webinar last week. For those who missed the live session, DeciBio's latest newsletter includes a link to the full replay. Hear from Precede Biosciences' CEO, Rehan Verjee, and other industry leaders on emerging trends and innovations in #LiquidBiopsy.
The amount of #LBx news in October was almost spooky! The last month brought a couple FDA approvals, new funding, and new studies.?? ? Clinical and Regulatory? The FDA approved Foundation Medicine's FoundationOne Liquid CDx to be used as a companion diagnostic for Itovebi in combination with palbociclib and fulvestrant for the treatment of PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer. The FDA also approved Exact Sciences’ Cologuard Plus test, the next generation multitarget stool DNA test, based on findings from the pivotal BLUE-C study where Cologuard Plus demonstrated 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% specificity with no findings on colonoscopy. ? ? Company Announcements & Product Launches? GeneCentric Therapeutics, Inc. announced the launch of its ExpressCT liquid biopsy platform that allows RNA expression and epigenomics to assessed in liquid biopsy samples, including blood and urine. InformedDNA and Phenomix announced a collaboration that integrates Phenomix’s saliva-based MyPhenome genetic obesity test with InformedDNA’s DNAimpact precision health platform, broadening access to genetics-based weight management care.?? ? Clinical Trials & Study Results? Myriad Genetics announced five research collaborations studying the use of MRD in various breast cancer settings using Myriad’s Precise MRD test. Research collaborations include predicting treatment response in adjuvant HR-positive patients, potentially guiding surgical decisions in newly diagnosed HR-positive patients, monitoring for recurrence across subtypes, optimizing therapy maintenance in HER2-positive advanced or metastatic patients, and monitoring ctDNA levels in high-risk patients from diagnosis through the adjuvant setting.? ? M&A | VC | Private Equity | Legal? aitiologic announced over €2.5M in total funding to date, which it will use to develop its AI-powered aitios platform for early disease detection and personalized medicine. Xgenera announced over ￡3m in funding, with investment led by QantX alongside a grant from NIHR (National Institute for Health and Care Research). Xgenera is developing miONCO, a blood-based multi-cancer screening test that measures microRNA expression.? ? Read the newsletter for more:??https://lnkd.in/g-2MFt-t ? Sign up to receive our Liquid Biopsy Newsletter in your email:?https://lnkd.in/gKQn7_zp ? The headlines have been handcrafted by Amal Thommil, Graham F., Nila Venkat, and Antony Awad?? ? #cancerdetection #earlydetection #precisionmedicine #productlaunches #cancermonitoring #liquidbiopsytesting?
Liquid Biopsy | October Round-Up 2024
DeciBio，发布于领英
-
#NEVYs24: We’re excited to share that Precede Biosciences has been nominated for Emerging Life Sciences Company of the Year by the New England Venture Capital Association! We're proud to be part of this esteemed group of innovators and look forward to attending the awards ceremony on December 5! Check out the full nominee list here: bit.ly/48yZ7pV #NEVCA #Innovation #PrecisionMedicine
-
-
We are pleased to announce the speakers for our upcoming webinar, Emerging Applications and Platforms in Liquid Biopsy, on Wednesday, November 6, 2024. Join us for this discussion led by: Rehan Verjee, Chief Executive Officer, Precede Biosciences Dawn Mattoon, Chief Executive Officer, Mercy BioAnalytics, Inc. Peter B., Chief Medical Officer, DELFI Diagnostics Sarah Clancey Overton, Director of RCM, Velsera Mark Sausen, Executive Director, Head of Technology Innovation, PGDx, Labcorp Together, our distinguished speakers will explore advancements in liquid biopsy, including innovations in early cancer detection, epigenomics, and targeted therapies, while addressing challenges in access and reimbursement. Webinar Details ?? Date: Wednesday, November 6, 2024 ? Time: 9:00 AM - 10:00 AM PST ??Register here: https://lnkd.in/gKZBQanP #precisionmedicine #liquidbiopsy
-